[Discussion] 503B is doing more work than we give it credit for
503B is doing more work than we give it credit for, which sounds obvious until you try to state the evidence for it.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
ask what the beyond-use date is based on
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
Reminder that nothing here is medical advice and this board cannot tell you which arrangement to choose.
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
a telehealth intake that asks nothing has told you what it is
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
if a clinic will not name the facility, that is your answer
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
Was there potency testing on the finished preparation, or only on the starting material?
Was there potency testing on the finished preparation, or only on the starting material?
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
ask which facility, then ask for their testing
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.
[deleted]
Who is the prescriber, and are they the same organisation as the pharmacy?
do not assume the concentration matches the branded product
do not assume the concentration matches the branded product
Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
- 1a telehealth intake that asks nothing has told you what it is14 comments in this branch · started by u/lipid_panel_larry